See Article page 811.
Presenter: Dr Paul Philipp Heinisch
Dr Edward Hickey
(Houston, Tex). Good morning, everybody. Ed Hickey from Texas Children's and previously
Toronto, where we had a pretty sizeable cohort of adults who had previously undergone
Bjork-modified Fontan procedures in the 1980s and 1990s. And, anecdotally, it was
clear to us actually at the time that they really did very well in the long-term,
and you have now shown that in what's a pretty elegant analysis and very well-written
manuscript, so congratulations to you and your coauthors. I have 3 general questions
for you. There's long been a recognition that some sort of contractional pulsatility
in the Fontan circuit would be beneficial. In fact, it's my understanding in the very,
very, very early Fontan procedures where valves were incorporated in the inferior
vena cava and pulmonary artery (PA), there was a thinking that the right atrial contraction
might contribute to pulmonary blood flow. That was quickly shown not to be the case.
But in the Bjork modification, you are necessarily incorporating the ventricle in
the circuit. It's unlike any other Fontan, which excludes the ventricle. So conceptually,
that will help with pulsatility with pulmonary blood flow. So, this also will make
sense. How can you tease out though, the relative contribution of that ventricle and
how it's contributing to pulmonary blood flow versus the fact that these really are
the very best Fontan patients? These are the tricuspid atresias who have had very
little in the way of prior palliation, most of them PA bounds or nothing versus many
of the other groups, the total cavopulmonary connection (TCPC), in particular. These
have a very high prevalence of right ventricle (RV)-dominant ventricles, multiple
complex prior palliations. They're not really apples and apples, are they?
Dr Paul Philipp Heinisch
(Munich, Germany). Thank you very much for your questions. Yes, you are completely
right. This is probably the best subset of patients we have in this patient collective.
If you look at our cohort, we had mostly patients with tricuspid atresia with a nominate
position of the arteries as well as some patients with double-inlet left ventricle
also with a known position of the arteries. When we now look at the function of the
right ventricle and the rudimentary right ventricle to the systolic function, we also
have to keep in mind the PA size and the pulmonary vascular resistance. And in the
previous studies, we could see that not so much the size of the right ventricle is
the deciding factor but more likely the size of the PAs and the pulmonary vascular
resistance. We've seen some effect of, let's say, RV growth in the long run, but in
initial phase, the RV size didn't have much of an effect on the pulsatility of those
patients.
Dr Hickey. The revision rates in Bjork-modified Fontan procedures are not insignificant
at all. In fact, they can be pretty horrible revisions. The pericardial backflow is
sitting right behind the sternum and it's just a sea of blood waiting for you. Once
you are inside the chest, what made you strategize between putting a valve in that
right atrial–RV connection versus taking it completely down to a TCPC? And then those
that you did take down to a TCPC, how did you manage the right ventricular cavity
and its outflow to the PAs?
Dr Heinisch. That's a very good question. Thank you. First of all, when we look at
the initial Fontan-Bjork procedure, he used in the beginning homografts and had problem
with the calcification rate and also reoperation. And we had switched to providing
the back wall just for a direct connection of the right atrial to the RV and used
also Gore-Tex for the initial procedures. We are now thinking if something like kind
of a return of the Fontan-Bjorks, we are looking into decellularized homografts as
well, if this might be an option in the long run. Regarding your question for the
takedown or a conversion to a TCPC, in initial Fontan-Bjork, we had to close the atrial
septal defect as well as the ventricular septal defect, and those patients, as far
as I can remember, we opened up the atrial septal defect again and close down the
PA for the TCPC procedure.
Dr Hickey. Okay. So, you left a blind-ending RV cavity.
Dr Heinisch. This was on one patient, actually.
Dr Hickey. Okay. Just one final question, just very briefly. So most contemporary
modern young surgeons are probably completely unfamiliar with what a Björk modification
is because the de facto norm nowadays is, at the age of 3 or 4, you do an extracardiac
or lateral tunnel Fontan. So, in 2023, now, when you have an infant with tricuspid
atresia in a reasonable-sized RV cavity, are you actually pursuing and advocating
for a Björk modification in the current era?
Dr Heinisch. At the moment, at this day, we are still using the staged TCPC procedure.
But due to the data we've shown, we are thinking about changing the procedure for
this subset of patients which are highly selected, but we are not there yet. We are
still discussing.
Dr Hickey. Okay. Thank you. Congratulations.
Dr Heinisch. Good.
Unidentified Speaker 1. What do you guys think? Are you guys going to try this after
seeing these data?
Yeah. Raise your hand if you're going to try it.
Unidentified Speaker 2. Can I ask a question? How do you know—and this is because
I've never done that procedure—which are going to be pulsatile, and which are not?
Dr Heinisch. You don't. Also, it's difficult to say. If you see no impact on the ventricular
septal defect closures and we see no impact on the RV cavity, most likely those patients
who have pulsatility have the factors of low PA pressure and equally sized and sufficiently
sized PAs.
Unidentified Speaker 2. Yeah. So, I guess that's my—
Dr Heinisch. [crosstalk] have to look at those factors.
Unidentified Speaker 2. Yeah. That's my point, that you don't know. So, the vast majority
of them weren't pulsatile, right? The only group that showed better are the ones that
are pulsatile. So, until you can figure that out, I don't see how it would be an improvement.
Go ahead.
Dr Christian Brizard
(Melbourne, Australia). Christian Brizard from Melbourne. It's the same debate as
biventricular repair versus Fontan, the quality of life versus the risk. Here you
are. It seems that you're promoting the quality of life of the very few that have
survived. We know from the Fontan registry in Australia and New Zealand, where we
have more than 200,000 patients now, that the Björk prognostic compared to TCPC is
very, very different. So, you're trying to introduce a solution that has proven to
have generated a much higher mortality risk in the long term for the very small benefit
in terms of exercise ability. Reinventing the wheel after 20 years of developing the
modern Fontan concept is a bit controversial, I would think. And also, the work from
the Fontan registry demonstrates that the most efficient way to have an effect on
the exercise ability in Fontan is the physical training, the diet, especially on tricuspid
atresia. What do you think?
Dr Heinisch. Let's take it back. We look at the pressures, and we look at difference
between TCPC and the Fontan-Björk. We see that TCPC had much lower PA pressures. However,
on the other side, when we look at the exercise data, we've seen better exercise data
in patients with the Fontan-Björk, and this is probably mostly due to the—in the pulsatile
group, to the better fusion or adaptive fusion into the pulmonary vascular bed as
well. And I don't think that we can change it for all patients. We only can describe
what we've seen in the past. Those patients with the right physiology in very selected
cases can have a proficiently good quality of life with the Fontan-Björk. However,
we're still having patients with a high rate of tachyarrhythmias of the reintervention
rate due to the stenosis of the RV connection as well. So yes, I agree. It's very
controversial. And we don't know if we're going to change our setup at the moment,
but it was very, very interesting to look at the data and see the difference in those
patients when we just look at the exercise capacity.
Unidentified Speaker 1. All right. Very quick question, multiple choice.
Unidentified Speaker 3. Yeah. Do you think that is related more to the pulsatility
or the low central venous pressure that we achieve with the valve in the tricuspid
position? In the [inaudible] normally after [inaudible], now we are pushing to recover
the right ventricle, and then we achieve a lower central venous pressure. The pressure
in this inferior vena cava is much less than when you have the Fontan procedure. And
this can explain the better result, especially with the PLE. Thank you.
Dr Heinisch. To be honest, I don't know. Honestly, I really don't know. If you look
at the data of 11 patients, to answer this question is just—the sample set is too
small.
Unidentified Speaker 1. Okay. We're going to move on.
[applause]
Conflict of Interest Statement
The authors reported no conflicts of interest. The Journal policy requires editors
and reviewers to disclose conflicts of interest and to decline handling or reviewing
manuscripts for which they may have a conflict of interest. The editors and reviewers
of this article have no conflicts of interest.